4D Molecular Therapeutics (FDMT)
(Delayed Data from NSDQ)
$23.25 USD
-0.28 (-1.19%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $23.21 -0.04 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
FDMT 23.25 -0.28(-1.19%)
Will FDMT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FDMT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FDMT
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates
Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
FDMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Other News for FDMT
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
4D Molecular Therapeutics new overweight at Barclays on genetic medicine platform
4D Molecular price target raised by $5 at RBC Capital, here's why
RBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)
4D Molecular initiated with bullish view at Barclays, here's why